50 Leukaemia
The adjectives ‘myeloid’ and ‘lymphoid’ refer to the predominant cell involved, and the suffix-cytic and -blastic to mature and immature cells, respectively. These characteristics can be determined by a combination of cellular appearances, surface antigen expression and cytogenetic features. The international standard for leukaemia classification is the WHO system (Swerdlow et al., 2008).
Epidemiology
Haematological malignancies account for only 5% of all cancers; of these, CLL is the most common form of leukaemia. UK incidence data are presented in Table 50.1. CLL mainly affects an older age group: 90% of patients are over the age of 50 and nearly two-thirds are over 60 years old at diagnosis. It rarely occurs in young people and is twice as common in men as in women. CML is primarily a disease of middle age with the median onset in the 40–50 year old age group, but it can occur in younger people.
New cases/year | Incidence per 100,000 of the population | |
---|---|---|
CLL | 2750 | 4.58 |
CML | 750 | 1.5 |
ALL | 650 | 1.00 |
AML | 1950 | 3.25 |
Aetiology
Pathophysiology
In leukaemia, the normal process of haemopoiesis is altered (Fig. 50.1). Transformation to malignancy appears to occur in a single cell, usually at the pluripotential stem cell level, but it may occur in a committed stem cell with capacity for more limited differentiation. Accumulation of malignant cells leads to progressive impairment of the normal bone marrow function.
Acute leukaemias
Classification of acute myeloblastic leukaemia
AML has traditionally been classified on the basis of morphological features of the disease. Subtypes displaying granulocytic, monocytic, erythroid and megakaryocytic differentiation can be demonstrated. Recently, the World Health Organization (WHO) has updated this system (Table 50.2). AML is now classified using a combination of morphological, genetic and immunological cell marker features (surface antigen expression) in an attempt to define disease groups of greater prognostic significance (Swerdlow et al., 2008).
Subgroup | Examples |
---|---|
AML with recurrent genetic abnormalities | Inversion chromosome 16 (inv 16) |
t(15;17) | |
t(8;21) | |
AML with multilineage dysplasia | |
Therapy-related AML | |
AML not otherwise classified | AML without maturation |
AML with granulocytic maturation | |
AML with granulocytic and monocytic differentiation | |
AML with monocytic differentiation | |
AML with erythroid differentiation | |
AML with megakaryocytic differentiation |
Classification of acute lymphoblastic leukaemia
As with AML, the WHO classification system takes account of morphological, genetic and immunological features. The disease is, however, mainly classified immunologically, based on the presence or absence of B- or T-cell markers (Table 50.3). Each subtype displays different clinical presentations, response to treatment and, ultimately, prognosis, with pre-B having the best prognosis and B-ALL the worst. It is worth noting that B-ALL (Burkitt’s type), which is associated with translocations of the myc gene normally located on chromosome 8, seems to be a morphologically and biologically distinct form of leukaemia.
Pre-B ALL | Possessing the common ALL antigen CD 10 |
---|---|
B cell type | B-ALL of Burkitt’s type |
T cell type | T-ALL |
Null | Non-B, non-T and lacking the common ALL antigen CD 10 |
Chronic leukaemias
Chronic myelocytic leukaemia
The characteristic feature of CML is the predominance of maturing myeloid cells in blood, bone marrow, liver, spleen and other organs. CML was the first cancer to be associated with a specific chromosomal abnormality: the Philadelphia chromosome translocation (Ph) seen in over 90% of cases. This is a translocation of genetic material between the long arms of chromosome 22 and chromosome 9. This results in the apposition of the BCR gene (chromosome 22) and the ABL gene (chromosome 9). This novel BCR-ABL gene encodes a fusion protein which has tyrosine kinase activity. This genetic event is believed to be crucial in the pathogenesis, or perhaps even to initiate the development, of CML since overactivity of the tyrosine kinase results in the uncontrolled growth characteristic of leukaemic cells (Cilloni and Saglio, 2009).
Clinical manifestations
Investigations
Examinations of peripheral blood and bone marrow are the key laboratory investigations carried out in cases of suspected leukaemia. However, some additional investigations can help in the diagnosis and classification of this group of diseases. Some of the main findings at diagnosis are presented in Table 50.4.
Treatment
Acute leukaemia
Acute lymphoblastic leukaemia
Treatment of ALL in childhood has been one of the success stories of the past 3 decades. Over 80% of children will achieve a remission lasting more than 5 years, and current studies are often focused on trying to identify the 20% of children with poor risk disease and treating them more aggressively (Vrooman and Silverman, 2009). Unfortunately, the results in adults are not so impressive. The combination of vincristine, prednisolone, anthracyclines and asparaginase induces CR in about 90% of children with ALL and 80% of adults, although sadly relapse is far more common in adults (Table 50.5). Other active drugs in the treatment of ALL include methotrexate, 6-mercaptopurine, cyclophosphamide and mitoxantrone.
Acute myeloblastic leukaemia (non-acute promyelocytic leukaemia)
As for ALL, the treatment of AML involves induction and consolidation chemotherapy. In AML therapy, however, the chemotherapy regimens used to achieve remission are much more myelotoxic, and patients require intensive supportive care to survive periods of bone marrow aplasia (Fig. 50.2). The pyrimidine analogue cytarabine has formed the basis of treatment for AML for 20 years. The addition of daunorubicin and oral thioguanine has achieved a CR rate of 75% in patients under the age of 60 years and about 50% in those over 60 years (Dohner et al., 2010). The precise dose and scheduling of these agents is continually being refined in order to improve the response rates. Despite the numbers of patients who achieve CR following induction therapy, the majority relapse, with only about 25% becoming long-term disease-free survivors (Stone et al., 2004). Thus, in common with ALL, additional post-remission therapy is required. Intensive consolidation chemotherapy with high-dose cytarabine and daunorubicin or amsacrine appears to improve survival rates to approximately 50% after 3 years, with even more encouraging results being obtained in patients under 25 years of age (Dohner et al., 2010; Robak and Wierzbowska, 2009). There is generally no role for maintenance therapy in AML. Similarly, CNS prophylaxis is not routinely indicated though patients thought to be at particularly high risk of CNS disease, such as those with testicular or sinus involvement, should receive prophylactic therapy.
Treatment of AML in relapse is difficult and the prognosis is generally poor. Encouraging results have been seen using a combination of fludarabine, cytosine arabinoside and granulocyte colony-stimulating factor (G-CSF). Novel approaches in AML therapy are often piloted in this group of poor-risk patients. A combination of anti-CD33 antibody, which targets myeloid blasts, with calicheamicin, an anthracycline antibiotic, is a promising and effective approach (Stone et al., 2004), but appears most effective when given in combination with conventional chemotherapy. A newly developed purine analogue, clofarabine, has also been shown to have activity against AML. This drug is a promising agent, particularly in the treatment of older patients, as pilot studies suggest that its toxic effects may be less severe than those associated with other chemotherapy regimens (Robak and Wierzbowska, 2009). 5-Azacytidine is also of interest, especially in older patients and those whose disease has evolved from myelodysplastic syndrome MDS. This agent inhibits DNA methyltransferase resulting in DNA hypomethylation. This process is thought to increase activity of some tumour suppressor genes resulting in anti-tumour effects. The agent has been shown to slow the rate of progression to AML in patients with high-risk myelodysplastic syndrome and is currently the subject of clinical trials in AML.
Acute Promyelocytic Leukaemia
This subtype of AML deserves special consideration as the treatment is quite different from that of other AML variants. APL is associated with the t(15;17) translocation which involves a genetic translocation of material between chromosomes 15 and 17. The disease is clinically characterised by the presence of disseminated intravascular coagulopathy (DIC) at presentation. Since these patients are so prone to life-threatening haemorrhage at diagnosis, the management of a new case of APL is considered a medical emergency. The leukaemic cells are exquisitely sensitive to all-trans retinoic acid (ATRA), which induces blast maturation and can induce remission when used as a single agent (Sanz et al., 2009; Soignet and Maslak, 2004). Using a combination of ATRA and anthracycline chemotherapy, it is now possible to achieve long-term cure in >80% patients. There are some data to suggest that the ongoing use of ATRA in consolidation and maintenance treatment improves outcome further. A number of studies have been published demonstrating the efficacy of arsenic trioxide (ATO) in treating relapsed or refractory APL. Comparison of ATRA and anthracyclines against ATO and ATRA is now the subject of a large UK study of newly diagnosed patients (AML 17). The latter regimen has the potential advantage of avoiding significant myelosuppression.